| abstract |
A novel oligosaccharide linker. The oligosaccharide linker is used to prepare an antibody-drug conjugate with site-specific linkage and an antibody-drug conjugate with two coupled drugs. The oligosaccharide linker comprises a biantennary N-linked glycan, a terminal sialic acid provided with a modification group Y-(CH2)n-X, and a terminal acetylglucosamine comprising an oxazoline. The antibody-drug conjugate and the antibody-drug conjugate with two coupled drugs can be used to prepare a pharmaceutical product for anti-tumor, anti-inflammation, anti-virus, anti-infection, or other forms of immunotherapy. |